Financial Performance - The company's operating revenue for 2021 was ¥3,612,045,255.57, representing a 5.01% increase from ¥3,439,840,440.43 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥77,295,070.82, a decrease of 13.53% compared to ¥89,392,934.21 in 2020[20]. - The net profit after deducting non-recurring gains and losses was ¥60,152,987.05, down 7.91% from ¥65,322,517.64 in 2020[20]. - The net cash flow from operating activities was ¥75,165,175.26, a significant decline of 51.45% from ¥154,814,640.09 in 2020[20]. - Basic earnings per share for 2021 were ¥0.23, a decrease of 14.81% from ¥0.27 in 2020[20]. - Total assets at the end of 2021 were ¥2,986,396,531.76, reflecting a 10.55% increase from ¥2,701,279,049.18 at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were ¥1,853,653,536.89, up 6.44% from ¥1,741,455,077.20 at the end of 2020[20]. - The weighted average return on net assets for 2021 was 4.30%, down 0.91 percentage points from 5.21% in 2020[20]. - The total profit for the year was 103 million yuan, which reflects a decline of 10.35% year-over-year[41]. - Total revenue for 2021 reached ¥3,612,045,255.57, a year-on-year increase of 5.01% compared to ¥3,439,840,440.43 in 2020[51]. Dividend Distribution - The company plans to distribute a cash dividend of 0.60 RMB per 10 shares to all shareholders, based on a total of 334,123,286 shares[8]. - The company distributed cash dividends of 20,047,397.16 yuan, accounting for 100% of the total profit distribution[126]. - The company approved a cash dividend of 0.70 yuan per 10 shares, totaling 23,388,630.02 yuan for the previous year[124]. Governance and Management - The company emphasizes the importance of accurate financial reporting, with key personnel affirming the report's authenticity and completeness[7]. - The board of directors has ensured that all members attended the meeting to review the annual report, highlighting governance practices[8]. - The company has a commitment to transparency, with its annual report available on the Shenzhen Stock Exchange website and other media[16]. - The company aims to enhance its governance structure through comprehensive reforms and the introduction of over 80 new talents[45]. - The company has established a responsibility accountability system for violations in business operations and investments[129]. - The company conducted internal control self-assessments and audits to enhance governance capabilities[129]. - The company has a diverse board with members holding various professional qualifications and experiences[108]. - The company is focused on enhancing its governance structure through independent oversight[109]. - The company maintained a structured approach to board meetings and decision-making processes, reflecting strong corporate governance practices[116]. Research and Development - Research and development expenses amounted to ¥33,024,800, representing a 23.47% increase year-on-year[44]. - The company achieved a "zero breakthrough" in drug consistency evaluation with the successful assessment of Clarithromycin tablets[44]. - The company established two R&D innovation platforms, including the National Synthetic Biology Shaoxing Demonstration Base, to support innovation in the biomedicine and health sectors[44]. - The company introduced three new health products and developed a phased research plan for a new analgesic drug[44]. - The company will increase R&D investment and strengthen collaborations with research institutions to mitigate risks associated with drug innovation and consistency evaluation[89]. Market and Industry Trends - The Chinese health industry market size reached ¥9 trillion in 2020 and is projected to grow to ¥13.4 trillion by 2024, indicating a compound annual growth rate of approximately 10.4%[30]. - The online pharmaceutical market in China was valued at ¥195.6 billion in 2020, with a year-over-year growth of 28.3%, and is expected to reach ¥226 billion in 2021, reflecting a growth rate of 15.5%[32]. - The health industry is expected to see unprecedented growth opportunities due to supportive national policies and increasing consumer health awareness, with a shift in demand from treatment to prevention and health management[74]. - The development of traditional Chinese medicine is positioned as a national strategy, with significant government support and policies aimed at promoting its innovation and integration into the healthcare system[75]. - Digitalization is expected to drive industry transformation, enhancing efficiency and enabling better patient-centered services through online channels and smart manufacturing[77]. Operational Performance - The company has a diverse business scope, including traditional Chinese medicine, chemical raw materials, and medical devices[17]. - The company expanded its retail chain by opening 4 new direct-operated stores and acquiring 5 stores, optimizing 16 existing stores[42]. - The company’s subsidiary, Zhejiang Zhenyuan Pharmaceutical Supply Chain Management Co., won a bid for the logistics distribution service project for medical supplies in Shaoxing City, enhancing its logistics capabilities[40]. - The company is focusing on digital transformation by establishing a digital pharmacy and implementing smart healthcare solutions[43]. - The company is actively adapting to the ongoing healthcare reforms and market competition, emphasizing innovation and collaboration across the healthcare ecosystem[36]. Environmental and Social Responsibility - The company has implemented measures to enhance governance and maintain investor interests, with no significant issues found during the governance self-inspection[133]. - The company has established a wastewater treatment facility with a daily processing capacity of 2,000 tons, utilizing advanced treatment processes to ensure compliance with discharge standards[138]. - The company has actively participated in social responsibility initiatives, providing over 18 million pieces of epidemic prevention materials and 150,000 bags of traditional Chinese medicine during the pandemic[141]. - Zhenyuan has established 12 community pharmacy service stations, enhancing healthcare accessibility in Shaoxing City, with one station recognized as a five-star service station[141]. - The company has adopted a "company + cooperative + farmer" model for traditional Chinese medicine cultivation, promoting sustainable agricultural practices and supporting local economies[142]. Financial Controls and Compliance - Zhejiang Zhenyuan Co., Ltd. maintained effective internal control over financial reporting as of December 31, 2021, according to the internal control audit report[133]. - The company reported zero significant defects in both financial and non-financial reporting for the year 2021[131]. - The internal control self-assessment report was fully disclosed on April 9, 2022, indicating a comprehensive evaluation of internal controls[131]. - The company has a 100% inclusion rate of subsidiaries in the internal control evaluation, covering total assets and revenue[131]. - The audit opinion for the financial statements was a standard unqualified opinion, issued by Tianjian Accounting Firm on July 7, 2022[188].

Financial Performance - The company's operating revenue for the third quarter of 2021 was ¥904,360,412.16, an increase of 4.74% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥12,961,008.30, a decrease of 42.07% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,581,130.50, down 55.35% from the previous year[5]. - The basic earnings per share for the period was ¥0.0388, reflecting a decline of 42.09% compared to the same period last year[5]. - Net profit for the first nine months was RMB 59,175,133.78, a decrease of 19.0% from RMB 73,014,248.13 in the previous year[25]. - Operating profit for the first nine months was RMB 75,162,288.25, down 18.6% from RMB 92,290,604.67 year-on-year[25]. - The company’s investment income was RMB 5,879,727.40, down from RMB 7,475,433.57 in the same period last year[25]. Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥2,798,597,112.81, representing a 3.60% increase from the end of the previous year[5]. - Total assets increased by 54,579,301.97 RMB, reaching 2,755,858,351.15 RMB[19]. - Total liabilities amounted to RMB 968,397,586.93, an increase from RMB 939,286,554.16 in the previous year, reflecting a growth of approximately 3.8%[24]. - Non-current liabilities totaled RMB 156,061,924.37, an increase from RMB 108,407,333.28, indicating a growth of approximately 44.0%[24]. - The total equity attributable to shareholders of the parent company was RMB 1,812,936,960.12, compared to RMB 1,741,455,077.20, representing a growth of approximately 4.1%[21]. Cash Flow - The net cash flow from operating activities was negative at -¥27,427,802.90, a decline of 153.49% compared to the previous year[5]. - Operating cash inflow for the first nine months of 2021 was RMB 2,691,524,934.42, an increase of 6.54% compared to RMB 2,526,158,645.67 in the same period last year[26]. - Operating cash outflow for the same period was RMB 2,718,952,737.32, up from RMB 2,474,886,165.18, resulting in a net cash flow from operating activities of RMB -27,427,802.90[26]. - Investment cash inflow decreased to RMB 417,612,400.60 from RMB 676,825,322.47, while investment cash outflow was RMB 573,142,233.78, leading to a net cash flow from investing activities of RMB -155,529,833.18[26]. - Financing cash inflow was RMB 50,000,000.00, while financing cash outflow totaled RMB 97,358,409.41, resulting in a net cash flow from financing activities of RMB -97,358,409.41[26]. - The company experienced a net decrease in cash and cash equivalents of RMB 280,333,693.88 during the reporting period[26]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 25,103[11]. - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 24.93% of shares, totaling 83,300,474 shares[11]. - The company has 31,225,514 shares with no restrictions on sale held by the largest shareholder[11]. - The total number of preferred shareholders is not applicable[13]. - The company is currently unknown if there are any related party relationships among the top shareholders[12]. Expenses and Investments - Research and development expenses increased by 32.65% to ¥22,181,208.87, primarily due to increased outsourcing costs[9]. - The company reported a significant increase of 240.09% in construction in progress, amounting to ¥16,967,802.88, attributed to the establishment of an emergency material reserve[9]. - The company’s prepayments increased by 47.65% to ¥44,045,149.55, due to changes in payment methods[9]. - Cash paid for purchasing goods and services increased to RMB 2,038,789,383.46 from RMB 1,788,933,930.54, reflecting a rise of 13.93%[26]. - Cash paid to employees rose to RMB 193,152,134.31 from RMB 165,469,006.77, indicating an increase of 16.74%[26]. Comprehensive Income - Other comprehensive income after tax was RMB 41,124,427.10, significantly higher than RMB 687,744.00 in the previous year[25]. - Total comprehensive income for the period was RMB 100,299,560.88, compared to RMB 73,701,992.13 in the same period last year[25].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,729,677,137.91, representing a 7.33% increase compared to CNY 1,611,550,088.62 in the same period last year[22]. - The net profit attributable to shareholders of the listed company decreased by 7.20% to CNY 44,020,728.52 from CNY 47,438,320.60 year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 18.86% to CNY 36,025,772.98, compared to CNY 30,310,583.01 in the previous year[22]. - The net cash flow from operating activities was negative at CNY -123,292,324.65, a decline of 407.09% from CNY -24,313,540.71 in the same period last year[22]. - The total assets at the end of the reporting period were CNY 2,733,339,137.07, up 1.19% from CNY 2,701,279,049.18 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 5.15% to CNY 1,831,100,973.62 from CNY 1,741,455,077.20 at the end of the previous year[22]. Business Expansion and Operations - The company expanded its retail chain by opening 2 new direct stores and acquiring 3 individual pharmacies, increasing the number of stores to nearly 150[36]. - The company successfully won the bid for the SPD project to provide logistics management and delivery services for medical supplies to the Shaoxing municipal hospital alliance[37]. - The company’s cold chain logistics capabilities were utilized to support the emergency distribution of COVID-19 vaccines, enhancing its logistics service offerings[37]. - The second maternal and infant care center opened in Keqiao, with orders increasing month by month, reflecting strong market demand[32]. - The company’s traditional Chinese medicine department was upgraded to a hospital, continuing to promote and develop specialized services in pediatrics and gynecology[36]. Research and Development - The company's R&D investment increased by 23.47% to ¥14,124,354.78 from ¥11,439,824.08 in the previous year[45]. - The company holds 22 invention patents and 2 design patents, showcasing its strong R&D capabilities in the pharmaceutical sector[41]. - The company acknowledges the high risks associated with drug research and development, which can take over 10 years from R&D to market[68]. - The company aims to strengthen collaboration with research institutions to accelerate drug innovation and consistency evaluation of generic drugs[68]. Financial Management - The company has not engaged in any major related party transactions or non-operating fund occupation during the reporting period, reflecting financial stability[90][92]. - A total of 25 million yuan was allocated for entrusted financial management, with 20 million yuan remaining unexpired, indicating prudent financial management practices[100]. - There were no major contracts or leasing arrangements reported during the period, suggesting a focus on core operations without external dependencies[96]. - The company has established an emergency response plan for environmental pollution incidents, ensuring preparedness and safety for employees[81]. Environmental Compliance - The company reported a total hazardous waste discharge of 2,336.93 tons, with no exceedance of discharge standards[77]. - The company has established a dedicated safety and environmental protection department to ensure compliance with environmental regulations[78]. - The company has implemented standardized management of hazardous waste, including classification and proper disposal[78]. - Zhejiang Zhenyuan Pharmaceutical has a wastewater treatment facility with a daily capacity of 2,000 tons, ensuring compliance with discharge standards through advanced treatment processes[79]. - The company’s RTO (Regenerative Thermal Oxidizer) for air pollution control is operating normally and meets national air quality standards[80]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,492[108]. - The total number of shares is 334,123,286, with 281,972,076 shares being freely tradable[116]. - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 24.93% of shares, totaling 83,300,474[108]. - The second-largest shareholder, Qiu Zhiwei, holds 1.89% of shares, totaling 6,322,880[108]. - The company has not undergone any changes in its controlling shareholder during the reporting period[116]. Accounting and Financial Reporting - The financial report for the first half of 2021 has not been audited[114]. - The company adheres to the accounting standards, ensuring that financial statements accurately reflect its financial position, operating results, and cash flows[119]. - The company uses Renminbi as its functional currency for accounting purposes[120]. - Financial assets are classified into three categories upon initial recognition: measured at amortized cost, measured at fair value with changes recognized in other comprehensive income, and measured at fair value with changes recognized in profit or loss[121]. Revenue Recognition - The company recognizes revenue based on the progress of performance obligations, confirming revenue when the customer obtains control of the goods or services[154]. - For sales of pharmaceuticals, revenue is recognized at the point of delivery to the buyer, with confirmed sales amounts and reliable measurement of related costs[155]. - Government grants are recognized when conditions are met, with monetary grants measured at received or receivable amounts, and non-monetary grants measured at fair value[156]. Liabilities and Provisions - Contract liabilities amounted to ¥13,022,649.87, remaining stable at 0.48% of total liabilities[53]. - Long-term borrowings and lease liabilities were not reported, while lease liabilities accounted for ¥34,847,551.12, representing 1.27% of total liabilities[53]. - Accounts payable increased to ¥441,837,894.61 from ¥413,743,538.14, representing a growth of 6.3%[198]. - The company reported a decrease in bank acceptance notes from ¥145,453,320.53 to ¥81,719,576.56, a decline of 43.8%[198]. Cash Flow and Liquidity - Cash and cash equivalents at the end of the period totaled ¥249,108,899.02, a decrease of 51.16% from ¥510,211,483.48 at the beginning of the period[169]. - The company’s financial position reflects a substantial decrease in cash reserves, indicating potential liquidity challenges moving forward[169]. - The company has a significant amount of cash tied up in bank deposits, totaling ¥240,892,792.15 at the end of the period[169]. Inventory and Receivables - The inventory balance at the end of the period is 583,823,688.23, with a provision for inventory depreciation of 719,458.11[181]. - The total accounts receivable at the end of the period is 18,965,195.17, an increase from the beginning balance of 14,910,149.19[178]. - The aging analysis of accounts receivable shows that 1-year and below accounts accounted for ¥514,062,572.01, with a bad debt provision of 5.00%[171].

Financial Performance - The company's operating revenue for Q1 2021 was CNY 855,334,430.90, representing a 12.16% increase compared to CNY 762,595,784.50 in the same period last year[7] - Net profit attributable to shareholders was CNY 18,110,636.45, up 24.08% from CNY 14,596,215.38 year-on-year[7] - The net profit after deducting non-recurring gains and losses surged by 151.17%, reaching CNY 15,560,052.52 compared to CNY 6,194,980.64 in the previous year[7] - The basic earnings per share increased by 24.03% to CNY 0.0542 from CNY 0.0437 in the same period last year[7] - Operating profit increased by 54.50% to ¥20.13 million, attributed to higher sales revenue and improved profitability[14] - The company reported a total comprehensive income of RMB 40,641,553.80 for Q1 2021, compared to RMB 163,869.52 in Q1 2020[32] - The company achieved an operating profit of RMB 20,128,523.33, compared to RMB 13,028,403.05 in Q1 2020, marking a significant improvement[32] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,672,154,857.45, a decrease of 1.08% from CNY 2,701,279,049.18 at the end of the previous year[7] - The net assets attributable to shareholders increased by 2.11% to CNY 1,778,176,967.62 from CNY 1,741,455,077.20 at the end of the previous year[7] - Total assets reached RMB 2,672,154,857.45, a slight decrease from RMB 2,701,279,049.18 at the end of the previous year[30] - Total liabilities were RMB 877,097,708.64, down from RMB 939,286,554.16, showing a decrease of about 6.6%[30] - Current liabilities for the first quarter of 2021 were CNY 630,247,092.72, while total liabilities stood at CNY 734,528,156.01[27] Cash Flow - The net cash flow from operating activities was negative at CNY -149,399,290.61, worsening by 23.70% compared to CNY -120,777,772.38 in the same period last year[7] - The cash inflow from operating activities totaled RMB 836,652,908.66, slightly down from RMB 841,389,588.74 in the same period last year[34] - The cash outflow from operating activities was RMB 986,052,199.27, compared to RMB 933,356,499.18 in the previous year, resulting in a net cash flow from operating activities of -RMB 149,399,290.61[34] - Cash inflow from investment activities amounted to RMB 262,592,506.85, while cash outflow was RMB 111,816,498.55, leading to a net cash flow from investment activities of -RMB 111,814,398.55[34] - The ending cash and cash equivalents balance was RMB 154,193,990.38, down from RMB 465,666,159.54 at the beginning of the period[34] Shareholder Information - The company reported a total of 26,609 common shareholders at the end of the reporting period[10] - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., held 24.93% of the shares, amounting to 83,300,474 shares[10] Research and Development - Ongoing research and development efforts are focused on enhancing product offerings and technological advancements[31] - Research and development expenses increased to RMB 6,738,176.89, reflecting the company's commitment to innovation[32] Tax and Other Expenses - The company reported a 52.80% decrease in taxes payable, amounting to ¥38.84 million, due to the payment of prior year's deferred taxes[14] - Tax expenses for the quarter were RMB 1,434,217.84, slightly higher than RMB 1,432,732.17 in the same period last year[32] Future Plans - The company plans to expand its market presence and invest in new product development to drive future growth[31]

Financial Performance - The company's operating revenue for 2020 was ¥3,439,840,440.43, representing a 6.06% increase compared to ¥3,243,149,411.12 in 2019[19]. - The net profit attributable to shareholders decreased by 57.75% to ¥89,392,934.21 in 2020 from ¥211,570,678.31 in 2019[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥65,322,517.64, a 7.34% increase from ¥60,854,530.04 in 2019[19]. - The net cash flow from operating activities increased by 30.80% to ¥154,814,640.09 in 2020 from ¥118,359,124.14 in 2019[19]. - Basic earnings per share decreased by 57.14% to ¥0.27 in 2020 from ¥0.63 in 2019[19]. - Total assets at the end of 2020 were ¥2,701,279,049.18, a 4.35% increase from ¥2,588,554,088.01 at the end of 2019[19]. - The net assets attributable to shareholders at the end of 2020 were ¥1,741,455,077.20, a 3.05% increase from ¥1,689,964,066.17 at the end of 2019[19]. - The total operating revenue for 2020 was approximately CNY 3.44 billion, representing a year-on-year increase of 6.06% compared to CNY 3.24 billion in 2019[44]. - The pharmaceutical industrial segment generated CNY 714.12 million, accounting for 20.76% of total revenue, which is a decrease of 2.74% from the previous year[44]. - The pharmaceutical commercial segment saw revenue of CNY 2.73 billion, making up 79.24% of total revenue, with an increase of 8.64% year-on-year[44]. - The health service segment achieved a remarkable growth of 127.37%, with revenue reaching CNY 60 million compared to CNY 26.39 million in the previous year[44]. Dividend Distribution - The company plans to distribute a cash dividend of 0.70 RMB per 10 shares to all shareholders, based on a total of 334,123,286 shares[5]. - In 2020, the company achieved a net profit of CNY 34,658,076.07, with a proposed cash dividend of CNY 0.70 per 10 shares, totaling CNY 23,388,630.02[85]. - The company distributed a cash dividend of CNY 0.60 per 10 shares in 2019, amounting to CNY 20,047,397.16, based on a net profit of CNY 32,171,579.78[84]. - The cash dividend for 2019 was ¥20,047,397.16, accounting for 9.48% of the net profit attributable to ordinary shareholders[86]. - The cash dividend for 2018 was ¥10,023,698.58, which was 14.14% of the net profit attributable to ordinary shareholders[86]. - The total distributable profit for the current period is ¥217,439,948.75, with the cash dividend amounting to 100% of the total profit distribution[87]. - The company has a clear cash dividend policy that aligns with its articles of association and shareholder resolutions[83]. - The company has maintained a consistent approach to profit distribution over the past three years, ensuring transparency and clarity in its dividend policies[82]. - The cash dividend for 2020 represents 26.16% of the net profit attributable to ordinary shareholders[86]. Risk Management and Governance - The company emphasizes the importance of accurate financial reporting and has declared that the financial report is true, accurate, and complete[4]. - The company is subject to various risks and has outlined potential future challenges and corresponding measures in its annual report[5]. - The company is focusing on enhancing its internal control management system to strengthen risk management and improve governance structure[41]. - The company plans to enhance its internal control system and improve governance structures to ensure compliance and risk management[76]. - The company faces risks from industry policy changes, market competition, and challenges in drug research and development, and will adapt its strategies accordingly[78][79]. - The company will continue to optimize its management and operational capabilities to respond to intensified market competition and evolving retail ecosystems[79]. - The company has committed to deepening cooperation with research institutions to accelerate drug innovation and consistency evaluations[79]. - The company has established a dedicated environmental protection department to oversee compliance with environmental laws, reporting no major environmental issues during the reporting period[120]. - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, through transparent information disclosure[113]. Innovation and Development - The company holds 22 invention patents and has established multiple research centers, showcasing its commitment to innovation and technology in pharmaceutical development[34]. - The company has made significant progress in product innovation, with the approval of injectable esomeprazole sodium and ongoing development of other key formulations[40]. - The company has strengthened its innovation-driven development strategy, focusing on new product R&D and collaboration with high-end research institutions[49]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency[150]. - The company is exploring participation in biopharmaceutical and health industry funds to identify new projects and growth points[74]. Market Performance and Expansion - The company generated over 150 million in tax-free sales from two specific pharmaceutical products, indicating strong market performance in its core offerings[27]. - The company operates nearly 150 retail chain stores, achieving recognition as one of the top 100 pharmacy chains in China, with two stores reporting sales exceeding 100 million[28]. - Online sales grew by over 90% during the year, driven by new e-commerce models such as mobile micro-stores and live streaming sales[39]. - The company added 8 new retail stores, bringing the total to 146, and established 20 new medicinal herb bases, totaling 80 bases over an area exceeding 17,000 acres[39]. - The company anticipates continued growth in the pharmaceutical industry, supported by increasing health awareness and government policies promoting traditional Chinese medicine[70]. - The company plans to enhance its brand and quality, aiming for improved value and market capitalization during the "14th Five-Year Plan" period[73]. - The company aims to expand its retail chain through a "four-in-one" strategy of direct sales, franchising, optimization, and acquisitions[74]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential deals[150]. Financial Management and Audit - The company received a standard unqualified audit report from Tianjian Accounting Firm for the 2020 financial year[166]. - The audit committee held 8 meetings during the reporting period to review the company's financial reports and internal control self-assessment[162]. - The supervisory board held 6 meetings to review the company's financial status and compliance with legal regulations[165]. - The company reported a good financial condition with no illegal activities during the reporting period[166]. - The internal control self-assessment report was disclosed on March 27, 2021, confirming that all units evaluated accounted for 100% of the company's total assets and revenue[170]. - The audit report was signed on March 25, 2021, by Tianjian Accounting Firm, confirming compliance with accounting standards[176]. - The company has established an independent financial management department, ensuring separation from the controlling shareholder[159]. - The company has a salary assessment system linking senior management's compensation to individual performance and company operations[168]. Environmental Responsibility - The company reported a total wastewater discharge of 894,000 tons, adhering to pollution discharge standards without exceeding limits[117]. - Zhenyuan Pharmaceutical's hazardous waste management includes a standardized storage facility with concrete flooring and emergency measures in place, ensuring safe handling and disposal[120]. - The company’s air pollution control system operates in accordance with national standards, ensuring emissions meet the required limits[122]. - The company has established a medical emergency material reserve library, providing significant support for public health emergency systems[111]. - The hazardous waste disposal is managed by qualified external units, ensuring compliance with environmental safety standards[120]. Shareholder Structure and Management - The total number of shares outstanding is 334,123,286, with limited shares increasing from 52,139,647 to 52,151,210 during the reporting period[126]. - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 24.93% of the shares, totaling 83,300,474 shares[129]. - The company has not undergone any changes in its controlling shareholder during the reporting period[134]. - The actual controller of the company is the Shaoxing Municipal Government State-owned Assets Supervision and Administration Commission, which has not changed during the reporting period[134]. - The company has not reported any changes in the equity situation of its controlling and participating shareholders during the reporting period[133]. - The current board members and senior management have a total of 86,250 shares held at the beginning of the period, with no new purchases or sales during the reporting period[143]. - The company has maintained stability in its management structure, with no significant changes in shareholding among current directors and supervisors[141]. - The company’s governance structure includes a mix of experienced professionals and independent directors, ensuring compliance and strategic oversight[145].

浙江震元股份有限公司 2020 年第三季度报告全文 浙江震元股份有限公司 董事长：陈云伟 $$=0=0\neq+\pi=+\pi$$ 0 浙江震元 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告 内容的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗 漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈云伟先生、主管会计工作负责人陈富根先生及会计 机构负责人（会计主管人员）丁佩娟女士声明：保证季度报告中财务 报表的真实、准确、完整。 非标准审计意见提示 □ 适用 不适用 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | | 上年度末 | 本报告期比上年 同期增减（%） | | --- | --- | --- | --- | --- | | 总资产（元） | 2,661,136,932.66 | | 2,588,554,088.01 | 2.80% | | 归属于上市公司股东的 | 1,740,414,881.60 | | 1 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥1,611,550,088.62, representing a 2.98% increase compared to ¥1,564,910,070.21 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥47,438,320.60, up 2.60% from ¥46,234,554.56 in the previous year[19]. - The basic earnings per share for the reporting period was ¥0.1420, reflecting a 2.60% increase from ¥0.1384 in the previous year[19]. - The company reported a decrease of 8.08% in net profit after deducting non-recurring gains and losses, amounting to ¥30,310,583.01 compared to ¥32,974,907.32 in the previous year[19]. - The company's main business revenue reached ¥1,606,225,370.25, an increase from ¥1,559,432,215.51 in the same period last year, representing a growth of approximately 3.8%[193]. - The net profit attributable to the parent company was ¥47,438,320.60, compared to ¥46,234,554.56 in the previous year, showing a slight increase of about 2.6%[192]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to -¥24,313,540.71, a 71.47% increase compared to -¥85,230,730.68 in the same period last year[19]. - The net cash flow from financing activities increased by 219.10% to ¥49,532,330.86, mainly due to new special loans for epidemic prevention materials[40]. - The company's investment income surged by 429.43% to ¥4,373,290.98, attributed to financial management gains from subsidiaries[40]. - The company made investments totaling ¥61,463,759.28 during the reporting period, a 100% increase compared to zero investment in the same period last year[46]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,589,301,963.06, a slight increase of 0.03% from ¥2,588,554,088.01 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased by 1.74% to ¥1,719,332,253.61 from ¥1,689,964,066.17 at the end of the previous year[19]. - Cash and cash equivalents increased to ¥270,618,709.20, representing 10.45% of total assets, up from 7.39% last year, a change of 3.06%[44]. - Accounts receivable decreased to ¥486,207,081.69, accounting for 18.78% of total assets, down from 22.66%, a reduction of 3.88%[44]. - Inventory rose to ¥505,586,185.80, making up 19.53% of total assets, compared to 21.44% last year, a decrease of 1.91%[44]. - The company reported a total of ¥8,511,207.18 in taxes and surcharges, slightly down from ¥8,609,934.68 in the previous year, a decrease of about 1.1%[195]. Operational Highlights - The company operates in the pharmaceutical industry, producing a variety of products including traditional Chinese medicine, chemical drugs, and medical devices, with a strong focus on high-tech and innovative products[24]. - The company has nearly 140 retail chain stores, with two individual pharmacies achieving sales exceeding 100 million yuan, and has been recognized in the top 100 Chinese pharmacy value rankings[25]. - The company added 9 new direct stores and 5 franchise stores in the first half of the year, expanding its retail network significantly[33]. - E-commerce sales increased by 136.4% year-on-year, with membership in the company's micro-mall growing from thousands to nearly 180,000[34]. - The company is actively involved in the development of new products, with the injection of esomeprazole sodium obtaining a drug registration certificate and ongoing research for other products[36]. Research and Development - Research and development expenses decreased by 36.08% to ¥11,439,824.08 from ¥17,896,747.64, primarily due to reduced outsourcing costs[38]. - The company is focusing on innovation and collaboration with high-end research institutions to strengthen its product portfolio and maintain competitive advantages[36]. - The company is advancing the standardization of traditional Chinese medicine pieces, having completed the application for a pilot project in Zhejiang Province and established 50 quality standards[35]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[8]. - The total number of shares outstanding is 334,123,286, with 52,139,647 shares (15.60%) under limited sale conditions and 281,983,639 shares (84.40%) under unrestricted sale conditions[90]. - The top 10 shareholders hold a total of 83,300,474 shares, which is 24.93% of the total share capital[93]. - The company has not conducted any poverty alleviation work or plans for future poverty alleviation initiatives during the reporting period[88]. Environmental Compliance - The company has a hazardous waste treatment facility that operates normally, ensuring compliance with environmental regulations[81]. - The wastewater treatment facility has a daily processing capacity of 2,000 tons, ensuring that wastewater meets discharge standards[83]. - The company adheres to air pollution discharge standards and operates its RTO equipment effectively[84]. - The company has established an emergency response plan for environmental pollution incidents to ensure safety and minimize losses[85]. Taxation and Regulatory Compliance - The effective corporate income tax rate for the subsidiary Zhejiang Zhenyuan Pharmaceutical Co., Ltd. is 15%, benefiting from high-tech enterprise status[146]. - The company has benefited from tax exemptions on certain services related to public health and essential goods during the COVID-19 pandemic[148]. - The company is subject to various tax rates, including a 25% corporate income tax rate for most entities, with specific reductions for qualifying subsidiaries[146]. Financial Instruments and Accounting Policies - The financial statements are prepared based on the going concern principle, with no significant doubts about the company's ability to continue operations for the next 12 months[108]. - The financial reports comply with the requirements of the enterprise accounting standards, reflecting the company's financial status, operating results, and cash flows accurately[109]. - The company adopted new financial instrument standards effective January 1, 2019, which changed the classification and measurement of financial assets[142]. - Revenue recognition is based on the assessment of contracts, identifying performance obligations, and determining the timing of revenue recognition[135].

证券代码：000705 股票简称：浙江震元 编号：2020-025 | --- | --- | |------------------------------|----------------------------------------------| | | | | 浙江震元股份有限公司关于召开 | 2019 年度网络业绩 | | | 说明会暨参加浙江辖区上市公司投资者网上集体接 | | | 待日活动的公告 | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没 有虚假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的沟通交流，浙江震元股份有限公司（以 下简称"公司"）将召开 2019 年度网络业绩说明会暨参加由中国证监 会浙江监管局指导、浙江上市公司协会与深圳市全景网络有限公司共 同举办的"凝心聚力 共克时艰"辖区上市公司投资者网上集体接待 日主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公 司提供的网上平台举行，投资者可以登录"全景·路演天下"网站 （http://rs.p5w.net）参与公司本次投资者网上接待日活动。网上 互动交流时间为 2020 ...

浙江震元股份有限公司 2020 年第一季度报告全文 浙江震元股份有限公司 2020 年第一季度报告全文 浙江震元股份有限公司 董事长： 陈云伟 二〇二〇年四月十七日 浙江震元股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司董事长陈云伟先生、财务总监金明华先生、财务经理丁佩娟女士声明： 保证季度报告中财务报表的真实、准确、完整。 所有董事均已出席了审议本次季报的董事会会议。 非标准审计意见提示 □ 适用 √ 不适用 第二节 公司基本情况 一、主要会计数据和财务指标 本报告期对以前期间财务数据是否进行了追溯调整或重述 | □ 是 否  | | | 单位：元 | | --- | --- | --- | --- | | | 本报告期 | 上年同期 | 本报告期比上 | | | | | 年同期增减 | | 营业收入 | 762,595,784.50 | 776,992,792.79 | -1.85% | | 归属于上市公司股东的净利润 | 14 ...

Financial Performance - In 2019, the company's operating revenue reached ¥3,243,149,411.12, representing a 13.47% increase compared to ¥2,858,058,626.14 in 2018[18]. - The net profit attributable to shareholders was ¥211,570,678.31, a significant increase of 198.47% from ¥70,884,105.74 in the previous year[18]. - The basic earnings per share rose to ¥0.63, marking a 200% increase from ¥0.21 in 2018[18]. - The net cash flow from operating activities surged by 364.35% to ¥118,359,124.14, compared to ¥25,488,980.32 in 2018[18]. - Total assets at the end of 2019 amounted to ¥2,588,554,088.01, an increase of 22.08% from ¥2,120,304,271.19 in 2018[18]. - The company's net assets attributable to shareholders increased by 18.77% to ¥1,689,964,066.17 from ¥1,422,866,650.44 in 2018[18]. - The company reported a quarterly revenue of ¥864,665,004.61 in Q4 2019, the highest among the four quarters[22]. - The net profit attributable to shareholders in Q4 2019 was ¥145,170,496.65, significantly higher than the previous quarters[22]. - The company reported a non-recurring gain of ¥150,716,148.27 in 2019, significantly up from ¥13,007,706.65 in 2018, indicating a substantial increase in non-operating income[24]. Dividend Distribution - The company plans to distribute a cash dividend of 0.60 RMB per 10 shares based on a total of 334,123,286 shares, amounting to a total cash payout of approximately 20 million RMB[5]. - The cash dividend per 10 shares for 2019 is set at CNY 0.60, an increase from CNY 0.30 in 2018[92]. - The cash dividend payout ratio for 2018 was 37.11%, indicating a strategic shift towards higher returns to shareholders in 2019[93]. Business Operations - The company operates in various sectors including traditional Chinese medicine, chemical raw materials, and medical devices, reflecting a diverse business model[15]. - The company has a comprehensive business scope that includes the sale of health supplements and medical equipment, indicating potential for market expansion[15]. - The company operates 8 subsidiaries, with a focus on traditional Chinese medicine and pharmaceutical production, including over 130 retail chain stores under the "Zhenyuan" brand[26][27]. - The company’s subsidiary, Zhenyuan Pharmaceutical, has over 50 years of experience in fermentation and drug synthesis, holding several leading products in the domestic market[26]. - The company has established a provincial-level engineering laboratory for traditional Chinese medicine, enhancing its production capacity to approximately 3,000 tons annually[28]. Market and Industry Trends - The pharmaceutical industry revenue reached CNY 734.26 million, a year-on-year increase of 10.71%[44]. - The revenue from pharmaceutical commercial operations was CNY 2.51 billion, growing by 14.31% compared to the previous year[44]. - The revenue from formulations increased by 20.74% to CNY 545.44 million, with significant contributions from key products exceeding CNY 150 million each[37]. - The company aims to leverage the growing health industry opportunities to achieve high-quality growth in 2019[36]. - The pharmaceutical distribution sector is shifting from organic growth to mergers and acquisitions, with companies seeking to enhance supply chain advantages[78]. Research and Development - The company has 22 invention patents and 2 design patents, showcasing its strong research and development capabilities in the pharmaceutical sector[33]. - Research and development (R&D) investment amounted to ¥32,871,317.59 in 2019, a decrease of 12.98% compared to ¥37,773,550.50 in 2018, with R&D expenses accounting for 1.01% of operating revenue[50]. - The company aims to improve its research and innovation capabilities by collaborating with high-end research institutions and developing competitive products[81]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with the board members affirming the authenticity of the annual report[4]. - The company’s board of directors includes experienced professionals, ensuring strong governance and strategic oversight[13]. - The company has maintained a stable relationship with its accounting firm, which has provided services for 23 years[105]. - The audit committee held 7 meetings during the reporting period to review the company's financial reports and internal control evaluations, ensuring compliance with regulatory requirements[166]. Environmental Responsibility - The company has a wastewater treatment facility with a daily capacity of 2,000 tons, ensuring compliance with discharge standards[125]. - The company maintains a strict hazardous waste management system, including a dedicated storage area and regular monitoring[124]. - The air pollution control system operates in compliance with national standards, ensuring no exceedances in emissions[126]. Employee and Management Structure - The company employed a total of 1,904 staff, with 506 in production, 355 in sales, and 696 in technical roles[154]. - The company has established a comprehensive training system to enhance the skills and management capabilities of mid-to-senior management and new employees, focusing on practical job skills and performance improvement[156]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 4.5928 million yuan[153]. Financial Position - The company has a registered capital of 100 million RMB, showcasing its financial foundation[15]. - The company’s cash and cash equivalents increased by 483.95% to ¥77,961,664.39 in 2019, compared to a decrease of ¥20,304,984.12 in 2018[51]. - The total liabilities increased from CNY 677,021,602.66 to CNY 695,218,002.66, an increase of CNY 18,196,400.00[99]. Strategic Initiatives - The company plans to enhance its supply chain services and explore new business models, including O2O pharmacies and SPD projects[80]. - The company is focused on risk management and enhancing internal management systems to ensure operational stability[82]. - The company has engaged in multiple asset disposals to improve its financial position and operational focus[71].